Piribo: New publication announcement, Commercial Insight: Neuropathic Pain

Introduction
Neurontin (gabapentin) has finally been knocked off the top spot as a result of fierce generic incursion. However, Pfizer's follow-on Lyrica (pregabalin), Lilly's Cymbalta (duloxetine) and Endo/Elan's Lidoderm (lidocaine patch 5%) are re-establishing market growth and laying the groundwork for new entrants.

Highlights
After a brief slump in 2005, the neuropathic pain market is forecast to grow to $5.5 billion by 2015, led by Lyrica and Cymbalta. Pfizer's commitment to neuropathic pain and Lilly's targeted approach are both effective strategies that can be utilized by all new entrants.The presence of generic gabapentin has introduced strong cost competition in the market. Setting a competitive price point for a new product is vital as healthcare payers continue to push for lower drug prices and generic prescribing although innovation is rewarded with a premium price and a high level of reimbursement in most countries.The current concerns surrounding the use of NSAIDs and opioids will be beneficial to neuropathic pain drug companies as physicians seek alternative analgesics for their patients. However, if they are to realize the full potential of the market, companies need to focus on expanding the patient potential by supporting physician education programs.

Scope
- Detailed analysis of key brands, with sales and volume forecasts to 2014 for the neuropathic pain indication alone
- Assessment of current and future opportunities and threats in the neuropathic pain market across the seven major pharmaceutical markets
- Consideration of key events that may affect revenues in each of the seven major pharmaceutical markets are applied and discussed
- Lifecycle management case studies show how previously successful strategies should be applied in today's market
Reasons to Purchase
- Quantify the future size of the neuropathic pain market in each of the seven major markets
- Understand key product differentiating factors that provide commercial advantages over existing therapies
- Compare market penetration and brand positioning strategies to those successfully employed by Pfizer, Endo, and Eli Lilly

Contents
Chapter 1 Executive Summary
Chapter 2 Market Definition And Overview
Chapter 3 Country Market Assessments
Chapter 4 Forecast Analysis
Chapter 5 Commercial Impact And Lifecycle Management: Case Studies
Appendix A - Market Data And Major Brand Key Facts
Appendix B - Market Forecast Data And Methodology
Appendix C

“Commercial Insight: Neuropathic Pain - A Plethora of Patient Segmentation and Product Differentiation Opportunities” is available from Piribo. For more information go to: http://www.piribo.com/publications/therapeutic/cns_neurology/commercial_insight_neuropathic_pain.html

Piribo Product ID: DAT530

About Piribo.
Piribo (http://www.piribo.com) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,800 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.